



ÖG HTG

JAHRESTAGUNG

**Österreichische Gesellschaft für
Herz- und thorakale Gefäßchirurgie**

PROGRAMM

Salzburg, 26. - 27. Mai 2026
Imlauer Hotel Pitter

www.oeghtg.at



KARDIOVASKULÄRE MEDIZINTECHNIK **DIE LEBEN VERÄNDERT**

Mit unseren zukunftsweisenden Technologien helfen wir Menschen mit Herz-Kreislauf-Erkrankungen, wieder ein aktiveres Leben zu führen.



Abbott
The Corporate Village, Da Vincilaan 11 Box F1, 1935 Zaventem, Belgien, +32 2 774 68 11
cardiovascular.abott

© 2023 Abbott. Alle Rechte vorbehalten.
MAT-2312102 v1.0 | Dieses Dokument ist für die Verwendung in EMEA zugelassen.

ALLGEMEINE INFORMATIONEN

VERANSTALTER:

Österreichische Gesellschaft für Herz- und thorakale Gefäßchirurgie

ZVR: 603588344

www.oeghtg.at

WISSENSCHAFTLICHE LEITUNG:

Prim. Univ.-Prof. Dr. Andreas Zierer, Präsident

Assoz. Prof. Dr. Nikolaos Bonaros, Präsident elect

Ass. Prof. Dr. Julia Dumfarth, Generalsekretärin

VERANSTALTUNGSORT:

Imlauer Hotel Pitter

Rainerstraße 6, 5020 Salzburg

ORGANISATION UND ANMELDUNG:



Medizinische Ausstellungs- und Werbegesellschaft

Freyung 6/3, 1010 Wien

Kontakt: Barbara Horak, Aylin Ilhan

Tel: +43 1 536 63 - 34 oder -15, kardio@maw.co.at

www.maw.co.at

ONLINE ANMELDUNG:

<https://registration.maw.co.at/kardiooeghtg26>



Diese Veranstaltung ist mit 9 DFP-Punkten der Österreichischen Ärztekammer approbiert. (FortbildungsID: 1056319)

DIENSTAG, 26. MAI 2026

17:30 - 19:00 POSTER SESSION JUNGES FORUM - Wine & Cheese
Faculty Dinner

MITTWOCH, 27. MAI 2026

WORKSHOP



Edwards

HERZCHIRURGISCHER KURS AN EINER HOCHMODERNEN SIMULATOR PLATTFORM
Simulation von MVR und Mitralklappenrekonstruktion

Die Sessions dauern jeweils 30 Minuten und finden im Zeitraum von 09:30 bis 11:30 sowie 13:30 bis 15:00 Uhr statt. Pro Slot können zwei Personen teilnehmen.

PROGRAMM Dienstag, 26. Mai 2026

17:30 - 19:00	POSTER SESSION JUNGES FORUM Moderation: Leo Winter-Pölzl (Innsbruck) Panelist: J. Gottsberger (Linz), A. Hannover (Wien)	Saal Auersperg
---------------	---	----------------

Poster Präsentationen:

1. Immune Senescence Drives Aortic Valve Calcification via $\gamma\delta$ T Cells
D. Seeberger, Innsbruck
2. Human Myocardial Transcriptomics Reveal Biglycan as a Central Angiogenic Mediator of Cardiac Shock Wave Therapy
F. Nägele, Innsbruck
3. Clinical Evaluation and Implementation of novel single shot cardioplegia Cardioplexol™
B. Winkler, Wien
4. Modulating Endothelial Plasticity to Treat Cardiac Fibrosis in Heart Failure
J. Eder, Innsbruck
5. Establishing Model Analysis of Hemodynamics as an Innovative Diagnostic Concept in Vascular Medicine
P. Benedikt, Linz
6. Longterm Outcome after Repair of Interrupted Aortic Arch in a Single Center
M. Kreuzer, Linz
7. PRESERVE Study- validation of graft storage solutions in clinical practice
J. Werdenits, Wien
8. Intensive lipid lowering therapies improve LDL-C goal achievement
H. Abfalterer, Innsbruck
9. Erstmalige LVAD-Implantation nach Tendyne™-TMVR - Fallbericht
B. Schachner, Linz

PROGRAMM Dienstag, 26. Mai 2026

10. Turning Surgical Waste into Scientific Opportunity: Epicardial Fat as a Reliable Source of Multipotent Adipogenic Stem/Progenitor Cells
E. Heuböck, Linz
11. Outcomes and surgical considerations of Aorto-Carotid and Aorto-Innominate Bypass in Upper Hemisternotomy for Innominate Artery Disease
P. Szalkiewicz, Linz
12. Präoperative Frailty bei Patient:innen mit Transkatheter- versus chirurgischem Aortenklappenersatz: Eine retrospektive vergleichende Analyse ernährungs- und muskelspezifischer Frailty-Marker
P. Benedikt, Linz
13. Minimally invasive aortic valve replacement by the novel transaxillary approach: considerations and first patient outcomes
P. Szalkiewicz, Linz
14. Transvenous Transseptal Mitral Valve-in-Valve Implantation for Stenosis of a Transcatheter Mitral Bioprosthesis
E. J. Manville
15. Behandlung der In-Stent-Restenose im Ramus interventricularis Anterior: Minimalinvasive Chirurgie im Vergleich zur perkutanen Intervention.
I. Gadelkarim
16. Association of Postoperative LDL Cholesterol and Statin Therapy with Survival After Coronary Artery Bypass Grafting
C. Engler, Innsbruck
17. Lipoprotein(a) Levels and Intensification of Lipid-Lowering Therapy After Cardiac Surgery
C. Engler, Innsbruck

Im Anschluss Faculty Dinner - Imlauer Sky

PROGRAMM Mittwoch, 27. Mai 2026

08:30 - 09:30 SESSION 1: AORTENKLAPPE Pitter Saal
Chairs: M. Grabenwöger (Wien), I. Coti (Wien)

1. **Targeting Endogenous Retroviruses Prevents Radiation-Induced Aortic Valve Calcification**
M. Graber, Innsbruck
2. **Surgical Infective Endocarditis: Forty-Five Years of Outcomes and Determinants of Mortality**
J. Hirsch, Innsbruck
3. **Routine CT-derived Pulmonary Artery Dimensions Independently Predict Mortality after Surgical Aortic Valve Replacement**
N. Clodi, Salzburg
4. **Bioprosthetic Aortic Valve Replacement Before 60: Acceptable Strategy or Risky Choice?**
Z. Arnold, Wien
5. **Five-year outcomes from the IMPACT registry**
I. Damian, Linz

09:30 - 11:30 HERZCHIRURGISCHER KURS AN EINER HOCHMODERNEN SIMULATOR PLATTFORM Pitter Saal 6
 (jeweils 30min Slots, 2 Personen pro Slot)

09:30 - 10:30 SESSION 2: MITRALKLAPPE Pitter Saal
Chairs: B. Zirngast (Graz), D. Wiedemann (St. Pölten)

1. **Evaluating the Feasibility of a Novel Device for Enhanced Control of ePTFE Chordal Length Assessment in Mitral Valve Surgery: A Porcine Model Study**
T. Poschner, Graz
2. **Phenotype-Driven Risk Stratification in Mitral Valve Surgery: Foundation for a Dedicated Mitral Risk Score**
R. Lohmann, Innsbruck
3. **Postoperative Atrial Fibrillation After Mitral Valve Surgery: Incidence, Persistence, and Prognostic Impact**
D. Fiesel, Innsbruck
4. **Minimally Invasive Mitral Valve Repair for Bileaflet Prolapse: Technical Success, Safety, and Long-Term Outcomes**
J. Spilka, Innsbruck
5. **Invited lecture: Endoskopische Mitralklappenrekonstruktion bei Mb Barlow**
A. Vötsch, St. Pölten

10:30 - 11:00 Kaffeepause in der Industrieausstellung Saal Auersperg

PROGRAMM Mittwoch, 27. Mai 2026

11:00 - 12:15 SESSION 3: Gender Pitter Saal
Chairs: J. Dumfarth (Wien), M. Grimm (Innsbruck)

1. Identical NT-proBNP Levels Correspond to Higher Mortality Risk in Women Undergoing Cardiac Surgery
L. Winter-Pözl, Innsbruck
2. CT-Derived Thoracic Muscle Attenuation Predicts Sex-Specific Mid- And Long-Term Mortality After Coronary Artery Bypass Grafting - Sex-Specific Insights Into Risk Stratification and Frailty Assessment
Ph. Krombholz-Reindl, Salzburg
3. Higher lipoprotein(a) burden in women undergoing coronary artery bypass grafting
H. Abfalterer, Innsbruck
4. A presentation-outcome paradox in women with acute type A aortic dissection
J. Gottsberger, Linz
5. Long-term outcomes after mitral valve surgery in women and men
A. Kahrovic, Wien
6. Bericht der Frauenbeauftragten der ÖGHTG
M. Kreuzer, Linz

12:15 - 13:30 Lunch Break und Industrieausstellung

13:30 - 15:00 HERZCHIRURGISCHER KURS AN EINER HOCHMODERNEN SIMULATOR PLATTFORM Pitter Saal 6
 (jeweils 30min Slots, 2 Personen pro Slot)

13:30 - 14:30 SESSION 4: Bypass Chirurgie Pitter Saal
Chairs: E. Ruttmann-Ulmer (Innsbruck), T. Schachner (Klagenfurt)

1. Colchicine Prevents Intimal Hyperplasia in Venous Bypass Grafts
V. Heim, Innsbruck
2. Durability of Coronary Bypass Grafts after Ascending Aortic Replacement
S. Schmidt, Innsbruck
3. Drei Dekaden MIDCAB: Retrospektive Analyse eines Single-Center-Erfolgsmodells
I. Gadelkarim, Leipzig
4. The value of extended follow-up in early phase device trials: Long-term outcomes of cardiac shockwave therapy beyond the CAST-HF trial
F. Nägele, Innsbruck
5. Failure to Achieve Guideline-Recommended LDL-C Targets After Coronary Artery Bypass Grafting: A Persistent Secondary Prevention Gap
V. Corradini, Innsbruck

PROGRAMM Mittwoch, 27. Mai 2026

14:30 - 15:30 SESSION 5: Miscellaneous: Congenital, HF, CAST, Aorten Pitter Saal
Chairs: J. Holfeld (Salzburg), M. Andreas (Wien)

- 1. Modulating Focal Adhesion Signaling to Prevent Fibrotic Remodeling in Heart Failure**
M. Ioannou-Nikolaidou, Innsbruck
- 2. Outcome of patients with Fontan associated protein losing diseases after Norwood palliation**
E. Sames-Dolzer, Linz
- 3. Clinical and Morphological Predictors of Outcome After Surgery for Acute Type A Aortic Dissection: A Single-Centre Study of 357 Patients**
F. Huber, Linz
- 4. Cardiac Rhythm Determines Prognostic NT-proBNP Thresholds in Mitral Valve Surgery**
V. Ennen, Innsbruck

15:30 - 15:45 Kaffeepause in der Industrieausstellung Saal Auersperg

15:45 - 17:00 QS2 Cardiac Database and Scientific Cooperations Pitter Saal
Generalversammlung
Chairs: A. Zierer (Linz), J. Dumfarth (Wien)

15:45 - 16:15 Aortendaten, laufende Projekte
A. Zuckermann, Wien

SCIENTIFIC AWARDS:



Wolfgang Denk Preis

Best of Abstracts

Poster Preis Junges Forum



16:15 - 17:00 Generalversammlung

MIT DER FREUNDLICHEN UNTERSTÜTZUNG VON



Edwards



AtriCure



Medtronic



Medtronic



Avalus Ultra™
bioprosthesis

Fit for the
future
right from
the start.

With every beat,
expect more.

The material shown should not be considered the exclusive source of information, it does not replace or supersede information contained in the device manual(s). Please note that the intended use of a product may vary depending on geographical approvals. See the device manual(s) for detailed information regarding the intended use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. For a MRI compatible device(s), consult the MRI information in the device manual(s) before performing a MRI. If a device is eligible for eIFU usage, instructions for use can be found at Medtronic's website manuals.medtronic.com. Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat® Reader with the browser. Medtronic products placed on European markets bear the CE mark and the UKCA mark (if applicable). For any further information, contact your local Medtronic representative.

13473220-en-gb-emea ©2024 Medtronic. Medtronic, Medtronic logo, and Engineering the extraordinary are trademarks of Medtronic. All other brands are trademarks of a Medtronic company.